Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Richard Young
Whitehead Institute for Biomedical Res, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Syros Pharmaceuticals, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Young is a founder, Director and consultant to Syros Pharmaceuticals. The interests of
the companies overlap with the research subject matter of the NIH funded award referenced
above. A management plan is required to assure that Dr. Young's relationship with the
companies will not influence the integrity of the research.
An iPSC based platform for functionally assessing genetic and environmental risk
Parkinson's disease (PD) is the second most common chronic progressive neurodegenerative disease worldwide, with a prevalence of more than 1% in the population over the age of 60, thus constituting a major global health problem of the aging population. While genome-wide association studies (GWAS) have pointed to more than 50 genomic loci that contribute to the risk of PD, little functional and molecular understanding has been gained into which and how these genetic variants contribute to the increased risk for PD, and this lack of insight has impeded the development of rational therapeutic strategies. The overall goal of this project is to establish a genetically defined experimental in vitro system for studying the molecular and biological mechanisms of sporadic PD in the dish and to identify novel genes that are causally involved in the pathogenesis of Parkinson's.
Filed on December 27, 2017.
Tell us what you know about Richard Young's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Richard Young filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | >$600,000 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | >$600,000 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | $100,000 - $149,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Marauder Therapeutics, Inc. | $100,000 - $149,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | $100,000 - $149,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | $100,000 - $149,999 |
| Richard A. Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals | $60,000 - $79,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Omega Therapeutics | $20,000 - $39,999 |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Marauder Therapeutics, Inc. | Value cannot be readily determined |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Omega Therapeutics | Value cannot be readily determined |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | Value cannot be readily determined |
| Richard A. Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals | Value cannot be readily determined |
| Richard Young | Whitehead Institute for Biomedical Res | Conflict of Interest | Syros Pharmaceuticals, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.